A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

NCT06770504 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Autoimmune Hemolytic Anemia
Anti-CD19 STAR T-cell Therapy
Failure ≥3 Lines of Therapies

Interventions

BIOLOGICAL: YTS109

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

[object Object]